Literature DB >> 4027532

The value of staging and serial follow-up investigations in patients with completely resected, primary, cutaneous malignant melanoma.

P A Kersey, N A Iscoe, J A Gapski, D Osoba, L From, G DeBoer, I C Quirt.   

Abstract

The purpose of this study was to determine the value of staging and serial follow-up investigations in newly diagnosed patients with completely excised primary cutaneous malignant melanoma. We reviewed the records of the 393 patients with completely excised primary malignant melanoma who were referred to the Ontario Cancer Institute and the Toronto-Bayview Regional Cancer Centre between 1 January 1978 and 31 March 1982. Initial investigations included history and physical examination in all 393 patients, complete blood count (199 patients), liver function tests (198 patients), urinary melanins (159 patients), chest X-rays (345 patients), whole lung tomography (182 patients), radionuclide liver-spleen scans (207 patients), and bone scans (116 patients), bipedal lymphangiograms (78 patients), CT scans of the chest (59 patients), and CT brain scans (51 patients). The clinical stage of ten patients was changed as a result of history and physical examination or lymphangiogram. All other investigations failed to detect metastatic melanoma. Follow-up investigations included history and physical examinations, complete blood counts, liver function tests, radionuclide liver spleen and bone scans. History and physical examinations, chest X-rays and patients' awareness of abnormalities were responsible for detection of subsequent melanoma recurrences. All other tests failed to identify metastatic melanoma at the time of its occurrence. Therefore, we recommend that initial staging investigations be limited to history and physical examination with clinical photographs, and baseline chest X-ray. We recommend that subsequent follow-up include only history and physical examinations and chest X-rays.

Entities:  

Mesh:

Year:  1985        PMID: 4027532     DOI: 10.1002/bjs.1800720810

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  6 in total

Review 1.  Long-term follow-up for melanoma patients: is there any evidence of a benefit?

Authors:  Natasha M Rueth; Kate D Cromwell; Janice N Cormier
Journal:  Surg Oncol Clin N Am       Date:  2015-01-24       Impact factor: 3.495

Review 2.  Variability in melanoma post-treatment surveillance practices by country and physician specialty: a systematic review.

Authors:  Kate D Cromwell; Merrick I Ross; Yan Xing; Jeffrey E Gershenwald; Richard E Royal; Anthony Lucci; Jeffrey E Lee; Janice N Cormier
Journal:  Melanoma Res       Date:  2012-10       Impact factor: 3.599

3.  Detection of melanoma nodal metastases; differences in detection between elderly and younger patients do not affect survival.

Authors:  S Kruijff; E Bastiaannet; A J H Suurmeijer; H J Hoekstra
Journal:  Ann Surg Oncol       Date:  2010-05-05       Impact factor: 5.344

4.  TRIM study protocol - a prospective randomized multicenter Trial to assess the Role of Imaging during follow-up after radical surgery of stage IIB-C and III cutaneous malignant Melanoma.

Authors:  Ylva Naeser; Hildur Helgadottir; Yvonne Brandberg; Johan Hansson; Roger Olofsson Bagge; Nils O Elander; Christian Ingvar; Karolin Isaksson; Petra Flygare; Cecilia Nilsson; Frida Jakobsson; Olga Del Val Munoz; Antonis Valachis; Malin Jansson; Charlotte Sparring; Lars Ohlsson; Ulf Dyrke; Dimitrios Papantoniou; Anders Sundin; Gustav J Ullenhag
Journal:  BMC Cancer       Date:  2020-12-07       Impact factor: 4.430

5.  Primary staging and follow-up in melanoma patients--monocenter evaluation of methods, costs and patient survival.

Authors:  U Hofmann; M Szedlak; W Rittgen; E G Jung; D Schadendorf
Journal:  Br J Cancer       Date:  2002-07-15       Impact factor: 7.640

Review 6.  Improving outcomes in patients with melanoma: strategies to ensure an early diagnosis.

Authors:  Rachel K Voss; Tessa N Woods; Kate D Cromwell; Kelly C Nelson; Janice N Cormier
Journal:  Patient Relat Outcome Meas       Date:  2015-11-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.